MedTrace Logo

Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)

NCT00927615 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 534

Last updated 2010-09-08

No results posted yet for this study

Summary

The primary objective of this study is to investigate whether intracoronary bolus administration of abciximab is superior to intravenous bolus administration in improving myocardial perfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Conditions

  • ST-Elevation Myocardial Infarction

Interventions

DRUG

abciximab

0.25 mg/kg body weight (intracoronary)

DRUG

abciximab

0.25 mg/kg body weight (intravenous)

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Felix Zijlstra, MD PhD · University Medical Center Groningen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-05-31
Completion
2011-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00927615 on ClinicalTrials.gov